Jan. 7, 2013
/PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that
, president and chief executive officer of ViroPharma, will provide an overview of the company's business, including additional maribavir clinical trial data, during the 31
Annual J.P. Morgan Healthcare Conference. The presentation will be webcast live at
6:30 P.M. ET
3:30 P.M. PT
Tuesday, January 8, 2013
and may be accessed via the company's website at
. The conference is being held at the Westin St. Francis Hotel in
. The company expects to release full-year 2012 financial results later in the first quarter of 2013.
"2012 represented a new beginning for ViroPharma. We believe our execution and achievements throughout the global organization during the year position the company very well for not only success in 2013, but also provides the opportunity for tremendous growth for our shareholders in the years ahead," stated Milano. "ViroPharma has moved beyond Vancocin
(vancomycin hydrochloride capsules, USP)
and now has a geographically diverse commercial portfolio and a robust, maturing development pipeline. The continued success of Cinryze
(C1 esterase inhibitor [human]), with unaudited 2012 U.S. net sales of approximately
, driven by over 900 active patients on prophylactic therapy, led the way. The commercial launches of Cinryze, Buccolam
(midazolam, oromucosal solution)
(hydrocortisone, modified release tablet) in
are also beginning to gain traction, and we believe that these products will ultimately become strong contributors to our overall growth in the years ahead."
Milano continued, "As we advance through 2013, we believe that our progress will clearly show ViroPharma to be well along the path that we laid out in our analyst day event this past September. The financial guidance we are providing this morning reflects strong enthusiasm for our products from our patients and their caregivers. We expect 2013 will also be a significant year in the advancement of our development programs. Success in 2013 could position us to be entering into phase 3 development of several products in 2014. As always, our global team embraces the challenges in front of us and is poised to continue executing on our long term plans which are designed to ultimately drive tremendous growth for our shareholders."